The Life Sciences team advised ElevateBio’s Life Edit Therapeutics, Inc. on their research and development collaboration with Novo Nordisk to discover and develop gene editing therapies against a select set of therapeutics targets.
The collaboration between the two companies allows for development of up to seven programmes. Under the agreement, Life Edit will receive an upfront cash payment and is eligible to receive potential development, regulatory, and commercial milestones of $335 million for each of the first two development programmes under the collaboration and up to $250 million for each of the following five development programmes under the collaboration.
ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come.
Life Edit Therapeutics, Inc., an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases and base editors.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.
The Goodwin team was led by Richard Hoffman, Erin Svokos, and Sarah Stoiber.
For more details, read the press release and article in Fierce Biotech.